Fundraising Fox
Sofie Biosciences
Culver City, US · Delaware corporation · 4 known investors
Find your way into Sofie Biosciences
Sign up to see every warm intro you have to Sofie Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sofie Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MP
Michael PhelpsFounder
SB
Stan BermanChief Financial Officer & Corporate Secretary2012–2018Stan Berman is an executive officer at Sofie Biosciences with prior experience as a Chief Financial Officer in life sciences and high technology companies, with expertise in financial planning, capital raising, and business development.
PP
Patrick PhelpsPresident, CEO, & Board Member, Co-FounderPatrick Phelps is founder and Executive Officer of Sofie Biosciences, a molecular imaging and radiopharmaceutical company. He has over 23 years of experience in diagnostic imaging technology and scaling companies from startups to publicly traded enterprises.
JC
Johannes CzerninNamed on SEC filing
JH
James HeathNamed on SEC filing
Board
AS
Ajit SinghBoard director
CW
Carl W. McKinzieBoard director
RD
Roy DoumaniBoard director
HM
Howard MaronBoard director
Investors · 4
Cycad Group LLClisted by Cycad Group LLCSanta Barbara
How we know: Cycad Group LLC's portfolio page · funding news · prnewswire.com · Not right? Tell us
Also in the syndicate · 3
MRM CapitalTata Industriesleadthe Cycad Group
Funding
SEC filings, press & company announcements$4.7M disclosed across 2 of 5 rounds · 2010–2019
- Undisclosed amountSeries AOct 2013
Tata Industries (lead), MRM Capital, the Cycad Group
Source ↗
▶$950KraisedJul 2019 · 14 investors · BiotechnologyRule 506(b)
▶$950KraisedJul 2019 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick E. PhelpsExecutive Officer, Director
- Joel CohenExecutive Officer
- Johannes CzerninDirector
- Ken Hermann, M.D.Director
- James HeathDirector
- Michael PhelpsDirector
- Ajit SinghDirector
- Howard MaronDirector
- Carl W. McKinzieDirector
- Philipp CzerninExecutive Officer
- Melissa Moore, Ph.DExecutive Officer
- Offering amount
- $950K
- Amount sold
- $950K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MofferedJun 2017 · BiotechnologyRule 506(b)
▶$16.8MofferedJun 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stan BermanExecutive Officer
- Roy DoumaniDirector
- Johannes CzerninDirector
- Patrick E. PhelpsExecutive Officer, Director
- Ajit SinghDirector
- Philipp CzerninExecutive Officer
- Michael PhelpsDirector
- Carl W. McKinzieDirector
- Howard MaronDirector
- James HeathDirector
- Melissa Moore, Ph.DExecutive Officer
- Offering amount
- $16.8M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.7MraisedJun 2016 · 9 investors · BiotechnologyRule 506(b)
▶$3.7MraisedJun 2016 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl W. McKinzieDirector
- Michael E. PhelpsDirector
- Johannes CzerninDirector
- Roy DoumaniDirector
- Stan BermanExecutive Officer
- Patrick PhelpsExecutive Officer, Director
- James HeathDirector
- Howard MaronDirector
- Ajit SinghDirector
- Offering amount
- $4M
- Amount sold
- $3.7M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $149.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.8M |
| Department of Energy | Phase II | 2012 | $995.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $145.2K |
| Department of Energy | Phase I | 2011 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded Sofie Biosciences?
- Sofie Biosciences was founded by Michael Phelps.
- Who are Sofie Biosciences's investors?
- Sofie Biosciences's investors include Cycad Group LLC.
- How much funding has Sofie Biosciences raised?
- Sofie Biosciences has disclosed $4.7M raised across 2 of its 5 known rounds.
- Where is Sofie Biosciences headquartered?
- Sofie Biosciences is headquartered in Culver City, US.